The present specification provides a hetero-cyclic compound and an organic light emitting device comprising the same.

A heterocyclic compound represented by Formula 1 and an organic electroluminescence device including the same in an emission layer. ##STR00001## In Formula 1, Z is represented by Formula 2-1 or 2-2. ##STR00002## In Formula 2-2, X.sub.1 to X.sub.3 are each independently CR.sub.10 or N, and at least one of X.sub.1 to X.sub.3 is N.

A heterocyclic compound represented by Formula 1 and an organic electroluminescence device including the same in an emission layer. ##STR00001## In Formula 1, Z is represented by Formula 2-1 or 2-2. ##STR00002## In Formula 2-2, X.sub.1 to X.sub.3 are each independently CR.sub.10 or N, and at least one of X.sub.1 to X.sub.3 is N.

A novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition containing the compound as an effective ingredient are disclosed. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.

A novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition containing the compound as an effective ingredient are disclosed. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.

The present disclosure is a pharmaceutical composition for the prevention or treatment of sepsis containing a thiamine derivative or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition of the present disclosure can be used for the prevention, alleviation, or treatment of sepsis by containing fursultiamine or allithiamine to inhibit the expressions of CD40, CD86, and TNF.

The present invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.

The present invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.

The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.